Plant Name: Lupinus luteus
Taxonomic Information:
Plant ID: NPO25469
Plant Latin Name: Lupinus luteus
Taxonomy Genus: Lupinus
Taxonomy Family: Fabaceae
Plant External Links:
NCBI TaxonomyDB:
3873
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
China; Italy; IndiaTraditional Medicine System:
Indian Folk; TCMGeographical Distribution:
India; Italy; China
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| PTPN2; | |
| MGAM; | |
| TDP1; BLM; HSD17B1; AOX1; | |
| ABL1; MAPK1; EGFR; | |
| ESR1; ESR2; | |
| ESRRB; ESRRA; | |
| MAOA; | |
| HIF1A; TP53; | |
| ABCG2; | |
| SLCO1B3; SLCO1B1; | |
| NPC1; RAB9A; THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 5 | TBXAS1 | Thromboxane-A synthase | P24557 | CHEMBL1835 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
| Hydrolase | MGAM | Maltase-glucoamylase | O43451 | CHEMBL2074 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | ABL1 | Tyrosine-protein kinase ABL | P00519 | CHEMBL1862 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0005496; steroid binding | 1.399E-09 | 3.045E-05 | ESR1, ESR2, ESRRA, ESRRB, HSD17B1, NPC1 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 1.742E-06 | 3.794E-03 | ESR1, ESR2 |
| BP | GO:0022414; reproductive process | GO:0001892; embryonic placenta development | 2.431E-06 | 4.018E-03 | EGFR, ESRRB, HIF1A |
| BP | GO:0002376; immune system process | GO:0001922; B-1 B cell homeostasis | 5.222E-06 | 7.066E-03 | ABL1, HIF1A |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 5.841E-06 | 7.066E-03 | ABL1, BLM, EGFR, ESR1, MAPK1, NPC1 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 9.491E-06 | 8.740E-03 | CYP1A2, EGFR, MAPK1 |
| MF | GO:0005488; binding | GO:0019901; protein kinase binding | 8.303E-06 | 8.740E-03 | ABL1, EGFR, ESR1, HIF1A, MAPK1, PTPN2, TP53 |
| MF | GO:0005488; binding | GO:0003690; double-stranded DNA binding | 8.649E-06 | 8.740E-03 | EGFR, ESR1, ESR2, ESRRA, ESRRB, HIF1A, TDP1, TP53 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.044E-05 | 8.740E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.044E-05 | 8.740E-03 | CYP1A2, CYP2C9 |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 1.146E-05 | 8.912E-03 | ABL1, BLM, EGFR, MAPK1, TP53, TSHR |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 1.257E-05 | 9.121E-03 | ABL1, EGFR, MAPK1, TP53 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.054E-04 | 2.669E-02 | EGFR, SLCO1B1, SLCO1B3, TSHR |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.627E-06 | 1.300E-04 | MAPK1, TP53, HIF1A, EGFR |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.831E-06 | 1.300E-04 | CYP2C9, MAOA, CYP1A2, AOX1 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 5.671E-06 | 2.684E-04 | MAPK1, TP53, HIF1A, ESR1, EGFR |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 7.766E-06 | 2.757E-04 | MAPK1, ESR1, EGFR, ESR2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 1.557E-05 | 4.081E-04 | MAPK1, TP53, ESR1, HIF1A |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.866E-05 | 4.081E-04 | MAOA, CYP1A2, AOX1 |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 5.165E-05 | 8.149E-04 | MAPK1, TP53, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 2.012E-05 | 4.081E-04 | MAPK1, TP53, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 4.132E-05 | 7.334E-04 | MAPK1, TP53, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 8.075E-05 | 1.000E-03 | MAPK1, TP53, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 8.453E-05 | 1.000E-03 | MAPK1, TP53, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.401E-04 | 1.171E-03 | ABL1, MAPK1, HIF1A, TP53, EGFR |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 8.075E-05 | 1.000E-03 | CYP2C9, CYP1A2, AOX1 |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 1.051E-04 | 1.013E-03 | MAPK1, TP53, EGFR |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 1.096E-04 | 1.013E-03 | MAPK1, ESR1, ESR2 |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 1.142E-04 | 1.013E-03 | ABL1, MAPK1, TP53 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 1.051E-04 | 1.013E-03 | SLCO1B1, SLCO1B3, ABCG2 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 2.057E-04 | 1.537E-03 | MAPK1, TP53, EGFR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 1.923E-04 | 1.517E-03 | ABL1, MAPK1, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05231 | Choline metabolism in cancer | 2.987E-04 | 2.121E-03 | MAPK1, HIF1A, EGFR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 3.164E-04 | 2.140E-03 | MAPK1, HIF1A, EGFR |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 4.046E-04 | 2.612E-03 | CYP2C9, MAOA, MAPK1 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 5.505E-04 | 3.176E-03 | ABL1, MAPK1, TP53, EGFR |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 4.952E-04 | 3.057E-03 | ABL1, MAPK1, TP53 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 7.979E-04 | 3.907E-03 | CYP2C9, MGAM, MAOA, HSD17B1, TBXAS1, CYP1A2, AOX1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 6.683E-04 | 3.389E-03 | MAPK1, TP53, EGFR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04630 | Jak-STAT signaling pathway | 1.101E-03 | 5.041E-03 | THPO, AOX1, PTPN2 |
| 09160 Human Diseases | 09161 Cancers | hsa05216 | Thyroid cancer | 6.457E-04 | 3.389E-03 | MAPK1, TP53 |
| Unclassified | Unclassified | hsa04320 | Dorso-ventral axis formation | 5.591E-04 | 3.176E-03 | MAPK1, EGFR |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00350 | Tyrosine metabolism | 9.417E-04 | 4.458E-03 | MAOA, AOX1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 6.457E-04 | 3.389E-03 | CYP2C9, CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Solid tumours | C00-D48 | EGFR; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | EGFR; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | ESRRA; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; EGFR; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; EGFR; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA; EGFR; |
| NA: NA | Menopausal disorder | NA | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ESRRA; |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | EGFR; |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | ESRRA; |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
| C00-D49: Neoplasms | Glioma | C71 | EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; EGFR; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | EGFR; |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; ESRRA; |
| C00-D49: Neoplasms | Colon cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | EGFR; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
| C00-D49: Neoplasms | Melanoma | C43 | EGFR; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA; |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | EGFR; |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ESRRA; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ESRRA; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
